JP2006141402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006141402A5 JP2006141402A5 JP2006000258A JP2006000258A JP2006141402A5 JP 2006141402 A5 JP2006141402 A5 JP 2006141402A5 JP 2006000258 A JP2006000258 A JP 2006000258A JP 2006000258 A JP2006000258 A JP 2006000258A JP 2006141402 A5 JP2006141402 A5 JP 2006141402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antisense compound
- antisense
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense effect Effects 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 11
- 102100032818 Integrin alpha-4 Human genes 0.000 description 8
- 108010041012 Integrin alpha4 Proteins 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- -1 oligonucleotides Chemical class 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/166,203 US5968826A (en) | 1998-10-05 | 1998-10-05 | Antisense inhibition of integrin α4 expression |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574727A Division JP3834204B2 (ja) | 1998-10-05 | 1999-08-19 | インテグリンα４発現のアンチセンス調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006141402A JP2006141402A (ja) | 2006-06-08 |
| JP2006141402A5 true JP2006141402A5 (enExample) | 2007-06-14 |
| JP4168285B2 JP4168285B2 (ja) | 2008-10-22 |
Family
ID=22602243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574727A Expired - Fee Related JP3834204B2 (ja) | 1998-10-05 | 1999-08-19 | インテグリンα４発現のアンチセンス調節 |
| JP2006000258A Expired - Fee Related JP4168285B2 (ja) | 1998-10-05 | 2006-01-04 | インテグリンα４発現のアンチセンス調節 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574727A Expired - Fee Related JP3834204B2 (ja) | 1998-10-05 | 1999-08-19 | インテグリンα４発現のアンチセンス調節 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5968826A (enExample) |
| EP (1) | EP1123414B1 (enExample) |
| JP (2) | JP3834204B2 (enExample) |
| AT (1) | ATE352639T1 (enExample) |
| AU (1) | AU759938B2 (enExample) |
| CA (1) | CA2345209C (enExample) |
| DE (1) | DE69934998T2 (enExample) |
| DK (1) | DK1123414T3 (enExample) |
| ES (1) | ES2279632T3 (enExample) |
| WO (1) | WO2000020635A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| DE19860642A1 (de) * | 1998-12-29 | 2000-07-06 | Deutsches Krebsforsch | Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| US20030154499A1 (en) * | 2001-06-08 | 2003-08-14 | Monika Wasel-Nielen | Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor |
| JP2006511207A (ja) * | 2002-08-19 | 2006-04-06 | ファルマシア・コーポレーション | 内皮特異分子−１発現のアンチセンス変調 |
| US9403908B2 (en) * | 2003-09-29 | 2016-08-02 | The Regents Of The University Of California | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| AU2005327506B2 (en) * | 2004-10-20 | 2010-07-08 | Antisense Therapeutics Ltd | Antisense modulation of integrin alpha4 expression |
| EA016838B1 (ru) * | 2005-06-07 | 2012-07-30 | Йельский Университет | Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt) |
| JP5547637B2 (ja) * | 2007-10-05 | 2014-07-16 | インデックス・ファーマシューティカルズ・アクチエボラーグ | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
| EP2318424B1 (en) * | 2008-06-23 | 2015-02-25 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| JP2013541520A (ja) * | 2010-09-17 | 2013-11-14 | アンチセンス・セラピューティックス・リミテッド | 幹細胞および／または前駆細胞を動員するための方法 |
| WO2014193625A1 (en) * | 2013-05-30 | 2014-12-04 | R-Pharm Overseas, Inc. | Fully human antibodies against human receptor integrin alpha-4 |
| WO2016179634A1 (en) * | 2015-05-11 | 2016-11-17 | Murdoch University | Multiple sclerosis treatment |
| EP3370734B1 (en) * | 2015-11-05 | 2023-01-04 | Children's Hospital Los Angeles | Antisense oligo for use in treating acute myeloid leukemia |
| JPWO2018174140A1 (ja) * | 2017-03-23 | 2020-04-09 | ナパジェン ファーマ, インコーポレテッドNapaJen Pharma, Inc. | 癌細胞の接着活性阻害剤 |
| WO2023039643A1 (en) * | 2021-09-20 | 2023-03-23 | Antisense Therapeutics Ltd | Methods and kits therefor |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| CN114887034B (zh) * | 2022-07-14 | 2022-10-28 | 中山莱博瑞辰生物医药有限公司 | LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途 |
| JP2025528873A (ja) * | 2022-08-16 | 2025-09-02 | ペルシュロン・セラピューティクス・リミテッド | Ｃｏｖｉｄ１９の神経学的急性後後遺症（ｎｐａｓｃ）の診断及び治療におけるバイオマーカー及びその使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696248A (en) * | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
-
1998
- 1998-10-05 US US09/166,203 patent/US5968826A/en not_active Expired - Lifetime
-
1999
- 1999-08-19 EP EP99942290A patent/EP1123414B1/en not_active Expired - Lifetime
- 1999-08-19 AU AU55703/99A patent/AU759938B2/en not_active Ceased
- 1999-08-19 ES ES99942290T patent/ES2279632T3/es not_active Expired - Lifetime
- 1999-08-19 WO PCT/US1999/018796 patent/WO2000020635A1/en not_active Ceased
- 1999-08-19 AT AT99942290T patent/ATE352639T1/de not_active IP Right Cessation
- 1999-08-19 US US09/377,309 patent/US6258790B1/en not_active Expired - Lifetime
- 1999-08-19 CA CA2345209A patent/CA2345209C/en not_active Expired - Fee Related
- 1999-08-19 DK DK99942290T patent/DK1123414T3/da active
- 1999-08-19 DE DE69934998T patent/DE69934998T2/de not_active Expired - Lifetime
- 1999-08-19 JP JP2000574727A patent/JP3834204B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-04 JP JP2006000258A patent/JP4168285B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006141402A5 (enExample) | ||
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2016530882A5 (enExample) | ||
| US20220170020A1 (en) | Antisense oligonucleic acid | |
| JP2019014733A (ja) | Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 | |
| JP2018150344A5 (enExample) | ||
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2018529732A (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2009506124A5 (enExample) | ||
| RS61528B1 (sr) | Oligonukleotidi za smanjenje ekspresije pd-l1 | |
| JP2004513626A5 (enExample) | ||
| RU2010116994A (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| WO2019215175A1 (en) | Oligonucleotides for modulating myh7 expression | |
| JP2016513110A5 (enExample) | ||
| CN120475978A (zh) | 用于抑制DM1蛋白激酶(DMPK)表达的RNAi剂、其组合物和使用方法 | |
| WO2013013165A2 (en) | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus | |
| JP2011505798A5 (enExample) | ||
| JP6875684B2 (ja) | 筋萎縮症治療用アンチセンス核酸 | |
| US20220042011A1 (en) | Antisense oligonucleotides targeting card9 | |
| KR19990022358A (ko) | 세포 증식을 억제하기 위한 ＩＬ-6 수용체 ｍＲＮＡ에 대한 안티센스 올리고뉴클레오티드의 용도 | |
| US20200216845A1 (en) | Antisense oligonucleotides for modulating rela expression | |
| WO2020038976A1 (en) | Antisense oligonucleotides targeting usp8 |